Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Down 8.0% in August

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 11,430,000 shares, a decrease of 8.0% from the August 15th total of 12,420,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is currently 10.4 days.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AUTL. Avoro Capital Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 1st quarter valued at about $78,765,000. Armistice Capital LLC raised its stake in shares of Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after acquiring an additional 2,487,778 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares in the last quarter. Finally, Great Point Partners LLC grew its holdings in shares of Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after purchasing an additional 2,275,000 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AUTL shares. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, June 17th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.70.

Autolus Therapeutics Trading Down 2.0 %

Shares of AUTL opened at $4.00 on Tuesday. Autolus Therapeutics has a 1-year low of $2.01 and a 1-year high of $7.45. The company has a market capitalization of $1.06 billion, a P/E ratio of -3.33 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The firm’s 50 day simple moving average is $4.10 and its 200 day simple moving average is $4.46.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Sell-side analysts forecast that Autolus Therapeutics will post -0.84 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.